James Crowe
Novel way to neutralize Rift Valley Fever Virus
Apr. 1, 2021—The discovery of monoclonal antibodies that neutralize Rift Valley Fever Virus — an emerging infection with pandemic potential — lays the foundation for future therapeutic antibody development.
Vanderbilt researchers take leadership role in COVID-19 vaccine development
Dec. 18, 2020—Moderna, remdesivir, AstraZeneca. VUMC’s experts have played an integral role in the development of these marquee COVID-19 therapeutics behind the scenes.
Exploiting viral vulnerabilities
Dec. 10, 2020—The isolation of human monoclonal antibodies against dangerous viruses including EEEV, Hendra and Nipah could offer new ways to treat and prevent these infections.
COVID-19 long-acting antibodies discovered by Vanderbilt University Medical Center move to phase 3 clinical trials
Oct. 13, 2020—AstraZeneca is advancing into phase 3 clinical trials with an investigational COVID-19 therapy of two long-acting antibodies discovered by Vanderbilt University Medical Center and optimized by AstraZeneca.
16 faculty members honored at Fall Faculty Assembly
Aug. 28, 2020—Chancellor Daniel Diermeier and Faculty Senate Chair Catherine McTamaney presented faculty awards for both spring and fall 2020 as part of the virtual faculty assembly held Aug. 27.
Antibody research at Vanderbilt University Medical Center shows promise in fight against COVID-19
Jul. 15, 2020—Based on positive results in preclinical studies reported today, potently neutralizing antibodies identified by researchers at Vanderbilt University Medical Center are showing promise as a potential therapy for preventing and treating COVID-19.
Research team isolates antibodies that may prevent rare polio-like illness in children linked to a respiratory infection
Jul. 3, 2020—Researchers at Vanderbilt University Medical Center, Purdue University and the University of Wisconsin-Madison have isolated human monoclonal antibodies that potentially can prevent a rare but devastating polio-like illness in children linked to a respiratory viral infection.
The Front Lines: Vanderbilt physicians, researchers join worldwide fight against COVID-19
May. 14, 2020—From the front lines of patient care to collaborating with scientists across the globe searching for treatments and vaccines, Vanderbilt University Medical Center and Vanderbilt University researchers have been working for months to combat the COVID-19 pandemic.
Antibodies eye Pacific Island “fever”
May. 14, 2020—Vanderbilt Vaccine Center team isolates monoclonal antibodies against the mosquito-borne Ross River virus, which causes rash, fever and debilitating muscle and joint pain lasting three to six months.
Antibody finding raises hopes for Marburg, COVID-19 treatments
Apr. 30, 2020—Monoclonal antibodies against Marburg virus — a more lethal cousin of the RNA virus that causes COVID-19 — may aid in the development of antibody "cocktails" to counter viral infection.
Vanderbilt University Medical Center and AstraZeneca join forces to identify potential COVID-19 treatments
Apr. 9, 2020—Vanderbilt University Medical Center and the global biopharmaceutical company AstraZeneca have joined forces to identify candidates for antibody-based treatments that could protect people exposed to the 2019 novel coronavirus disease, COVID-19.
Researchers developing potential coronavirus antibody therapies
Apr. 8, 2020—Vanderbilt University Medical Center is teaming up with academic, governmental and corporate partners in an unprecedented, fast-tracked global effort to develop antibody-based treatments to protect people exposed to the 2019 novel coronavirus disease, COVID-19.